NCT02448537View on ClinicalTrials.gov

A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

April 1, 2019

Conditions
Metastatic Sarcoma
Interventions
DRUG

PM01183

DRUG

Doxorubicin

DRUG

Gemcitabine

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

PharmaMar
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

PharmaMar

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT02448537 - A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas | Biotech Hunter | Biotech Hunter